MIPOL1-ETV1 GENE REARRANGEMENTS

• US 20110028336A1
• Filed: 07/03/2008
• Published: 02/03/2011
• Est. Priority Date: 07/06/2007
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Dhanasekaran, Saravana Mohan, Chinnaiyan, Arul M., Tomlins, Scott
• Granted Patent: US 9,303,291 B2
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed.

Claims

1. A method for detecting prostate cancer comprising detecting the presence of a MIPOL1-ETV1 genetic rearrangement in a biological sample, wherein the presence in the sample of the genetic rearrangement is indicative of prostate cancer in an individual from whom the sample was derived.

2. The method of claim 1, wherein detecting the MIPOL1-ETV1 genetic rearrangement comprises detecting a chromosomal rearrangement of genomic DNA that comprises MIPOL1 genetic material and ETV1 genetic material in the same genomic region.

3. The method of claim 2, wherein detecting the chromosomal rearrangement of genomic DNA uses a nucleic acid sequencing technique.

4. The method of claim 2, wherein detecting the chromosomal rearrangement of genomic DNA uses a nucleic acid hybridization technique.

5. The method of claim 4, wherein detecting the chromosomal rearrangement of genomic DNA uses a nucleic acid hybridization technique selected from the group consisting of:

in situ hybridization (ISH), analysis of hybridization to a microarray of probes, and Southern blot analysis.

6. The method of claim 2, wherein detecting the chromosomal rearrangement of genomic DNA uses a nucleic acid amplification method.

7. The method of claim 6, wherein the nucleic acid amplification method used is selected from the group consisting of:

polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), transcription-mediated amplification (TMA), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA).

8. The method of claim 1, wherein the sample is selected from the group consisting of tissue, blood, plasma, serum, urine, urine supernatant, urine cell pellet, semen, prostatic secretions and prostate cells.

9. A composition for detecting a MIPOL1-ETV1 genetic rearrangement associated with prostate cancer comprising at least one of the following:

(a) a probe comprising a sequence that hybridizes specifically to a junction at which an ETV1 gene is inserted into a MIPOL1 gene;

(b) a first probe comprising a sequence that hybridizes specifically to a MIPOL1 gene and a second probe comprising a sequence that hybridizes specifically to an ETV1 gene;

or

(c) a first amplification oligonucleotide comprising a sequence that hybridizes specifically to a MIPOL1 gene and a second amplification oligonucleotide comprising a sequence that hybridizes specifically to an ETV1 gene and a means for detecting an amplified product.

10. The composition of claim 10, wherein the means for detecting an amplified product in (c) is selected from the group consisting of probes, intercalating dyes and labeled amplification oligonucleotides.